Introduction
This review will cover the therapeutic development, validation, optimization, and clinical potential of intracellular antibody fragments, either as single-chain Fvs (scFvs) or single domains (dAbs, nanobodies; VH; VHH and VL) ( Table 1 ). The advantages of intrabodies are most apparent when considering the earliest steps in the triggers of neurodegenerative diseases of misfolding proteins. These origins are largely intracellular; therefore, an approach that allows modulation of critical proteins inside cells can be especially powerful. The approach also allows targeting of proteins that are post-translationally modified and/or specific conformers. Potential general intracellular physiologic targets are summarized in Fig. 1 , and include enhanced turnover, manipulation of subcellular compartmentalization (e.g., nuclear vs. cytoplasmic), and blocking sites of modifications and cleavage. There are additional valuable functions of such engineered antibody fragments including in vivo and in vitro diagnostics, as cofactors to facilitate crystallography to enable further novel drug development, and as extracellular therapeutic reagents (generally delivered as proteins). These are beyond the scope of this review and are in some cases covered by other manuscripts (Chatterjee and Kordower, 2019; Denis et al., 2019) in this special issue. et al., 1996) . It is increasingly appreciated that the antigen binding site may primarily reside on only one of the two chains, with the noncontacting chain stabilizing the correct folding of the binding chain. When the intrabody is expressed intracellularly from a gene, the secretory signal is often removed or not included in the clones. This should give the highest cytoplasmic levels of the polypeptide. However, as noted in some examples below, cells can take up extracellular proteins via the endosomal/ lysosomal system. Depending on exactly where in the cell the target is localized, this can be valuable. The scFv size is generally in the range of 250 amino acids (AA). Single-domain antibodies/nanobodies (VH or VL) are 125-140 AA in length and may have additional advantages in terms of size and use in multiplexes; however, the diversity of the antigens bound may be lower, especially for longer linear peptides. Camelid nanobodies are small heavy-chain-only antibody fragments (VHH) from naturally occurring heavy-chain only antibodies made in alpacas, llamas, camels and guanacos (Muyldermans et al., 2009) . These naturally evolved nanobodies may be especially stable and have been shown to fold correctly under a wide range of conditions. There are currently 11 human clinical trials of nanobodies in the NIH database, although none is for neurological diseases (https://clinicaltrials.gov/). Multiplexed nanobodies may allow the equivalent of avidity (cumulative effect of individual affinities) when the individual nanobodies recognize different epitopes of the same protein target (Moayeri et al., 2016; Schmidt et al., 2016) .
Selection methods include cloning the VH and VL domains from an existing monoclonal antibody (mouse or human), which has the advantage that the epitope and, in some cases, clinical effects, are known. However, only a fraction of these will be soluble in the reducing environment of the cytoplasm, leaving a choice between further engineering from a promising monoclonal, and starting with a candidate Table 1 Intrabodies targeting disease proteins of central nervous system disorders.
Huntington's disease protein target: huntingtin
Intrabody
Species Antigen Publications scFv-C4 Human scFv HTT-N17 (Butler and Messer, 2011; Butler et al., 2014; De Genst et al., 2015; Hathorn et al., 2011; Kvam et al., 2010; Lecerf et al., 2001; McLear et al., 2008; Miller et al., 2005b; Murphy and Messer, 2004; Snyder-Keller et al., 2010; Wolfgang et al., 2005) 
VL12.3
Human VL HTT-N17 (Butler et al., 2014; Colby et al., 2004a; Colby et al., 2004b; Southwell et al., 2011a; Southwell et al., 2008; Southwell et al., 2009) 
MW1
Mouse scFv HTT-polyQ (Khoshnan et al., 2002; Ko et al., 2001 ) MW2
Mouse scFv HTT-polyQ (Khoshnan et al., 2002; Ko et al., 2001 ) MW7
Mouse scFv HTT-PRR (Khoshnan et al., 2002; Ko et al., 2001; Southwell et al., 2008) Happ1 Human VL HTT-PRR (Southwell et al., 2008; Southwell et al., 2009) Happ3 Human VL HTT-PRR (Southwell et al., 2008 ) EM48
Mouse scFv HTT-Exon1 (Wang et al., 2008) 
INT41
Human scFv HTT-PRR (Amaro and Henderson, 2016 ) 6E
Human scFv Fibrillar mHTT (Butler and Messer, 2011; Kvam et al., 2009) Synucleinopathies protein target: α-synuclein Intrabody Species Antigen Publications D5
Human scFv Oligomeric α-syn (Emadi et al., 2007; Emadi et al., 2009; Joshi et al., 2012; Kvam et al., 2010; Spencer et al., 2016; Valera et al., 2017) 
10H
Human scFv Oligomeric α-syn (Emadi et al., 2009; Joshi et al., 2012; Spencer et al., 2017 ) D10
Human scFv Pan-specific α-syn (Joshi et al., 2012; Spencer et al., 2017; Zhou et al., 2004 ) VH14
Human VH α-syn AA 53-87 (Butler et al., 2016; Joshi et al., 2012; Lynch et al., 2008) 
NAC32
Human scFv α-syn AA 53-87 (Lynch et al., 2008) 
6E
Human scFv Fibrillar α-syn (Kvam et al., 2009; Kvam et al., 2010) Nbsyn2 Camelid VHH α-syn AA 118-131 (Butler et al., 2016; Guilliams et al., 2013) Nbsyn87
Camelid VHH α-syn AA 137-140 (Butler et al., 2016; Chatterjee et al., 2018; Guilliams et al., 2013) Alzheimer's disease protein target: β-amyloid Intrabody Species Antigen Publications scFvAβ IB scFv Aβ1-42 (Sudol et al., 2009) Tauopathies Protein Target: Tau  Intrabody  Species  Antigen  Publications  scFv#2 Human scFv tau 151-441 (Di Primio et al., 2016; Melchionna and Cattaneo, 2007; Visintin et al., 2002) 
scFv-RN2N
Mouse scFv 2 N tau (Nisbet et al., 2017) Human scFv SOD1 (Ghadge et al., 2019; Ghadge et al., 2013) 
B12
Human scFv SOD1 (Ghadge et al., 2019; Ghadge et al., 2013) 
D3H5
Mouse scFv G93A human SOD1 (Patel et al., 2014) TDP-43 proteinopathy protein target: TDP-43 Intrabody Species Antigen Publications VH1Vk9
Mouse scFv RNA recognition motif 1 (RRM1) (Pozzi et al., 2019) VH7Vk9 Mouse scFv RNA recognition motif 1 (RRM1) (Pozzi et al., 2019) A. Messer and D.C. Butler Neurobiology of Disease 134 (2020) 104619 pool that is most likely, on the basis of charge distribution, to be soluble (Kvam et al., 2010) . Libraries in which a high diversity of scFv or dAb clones are displayed on the surface of phage or yeast offer the option of starting with human sequences, with some preliminary tests of solubility based on periplasmic or surface expression, and selection in vitro. Iterative cycles of mutagenesis and selections can be employed to increase solubility and/or affinity; e.g. (Colby et al., 2004a; Colby et al., 2004b) for anti-N-terminal HTT1-20. Structure-based computational methods have also been utilized to optimize binding affinities; e.g., (Mahajan et al., 2018) for the non-β-amyloid component (NAC) region of α-syn. These approaches offer the option of increasingly sophisticated control of both on and off-rates, which will allow fine-tuning of pharmacodynamic functions. Examples of the neurological disease application of several of these approaches, with subsequent engineering, will be shown below. With current high-throughput sequencing, it is also now possible to immunize an animal with the antigen of interest, collect peripheral blood monocytes (PBMCs) at the height of the immune response, and deep sequence directly without producing a phage or yeast library. The most prevalent clones will then be identified using bioinformatics, and then tested against antigens. This offers the possibility of sampling multiple steps in the affinity maturation process, and of finding multiple epitopes. It could also be a valuable approach if lower affinities would be the most functional for a given application.
Although there is a significant literature on the structural basis of affinity, stability, and solubility of antibody fragments, we have found that the cellular cytoplasm, particularly within neurons that are already under proteostatic stress, is not yet a predictable environment.
Candidate clones must therefore be tested empirically, using model cell (preferable human stem cells differentiated along neuronal pathways) and animal systems that correlate as closely as possible with the proposed clinical use.
There are many considerations in the choice of selection methods, epitope conformations in context, solubility (particularly with single domains), and whether the highest affinity is optimal for the application. These are covered in detail in (Butler et al., 2012) . In summary, in vitro and in situ selection conditions will of necessity differ from intracellular conditions, particularly when cells are stressed. However, judicious initial screening has the potential to generate valuable lead Figure 1 . Schematic overview of intrabody mechanisms of action. Intrabodies can be used to inhibit protein-protein interactions including phosphorylation, pathogenic misfolding, and proteolytic cleavage. Additionally, they can be engineered to re-direct their antigens to cellular organelles (e.g., nucleus or proteasome).
Fig. 2.
General structure of antibody fragments. A. Conventional IgG immunoglobulin antibodies are composed of two heavy and two light chains. The heavy chains consist of one variable domain (VH) and three constant domains (CH1, CH2, CH3). The light chains have one variable domain (VL) and one constant domain (CL). The constant domains are joined by disulfide binding (e). The antigen binding fragment (Fab) is the region of an antibody that binds to antigens and is composed of one constant and one variable domain, each with a heavy and a light chain. The fragment crystallizable region (Fc region) is made up of only constant heavy domains. B. Camelid antibody is composed of two heavy chains, with a single variable domain (VHH). C. An scFv is comprised of the shortest variable-region fragment (Fv) of the VH and VL joined together by a polypeptide linker (▪▪▪). D. Single domain antibodies (dAb) are often referred to as nanobodies due to their size (~14kD).
candidate intrabodies that can be further characterized in situ, as previously reviewed, and detailed below (Cardinale and Biocca, 2008; Messer et al., 2009; Messer and McLear, 2006; Miller et al., 2003; Zhou and Przedborski, 2008) . Lower affinities may be sufficient for many applications and may be preferable when the goal is intrabody recycling or for use as a non-perturbing probe. Antibody engineering can be used to modulate a wide range of characteristics.
Delivery using gene therapy
A significant advantage of the antibody fragments is that they are both engineered and can be delivered as genes. The field of gene therapy for the nervous system has undergone explosive growth in the past 5 years, with human clinical trials for gene replacements in progress (www.clinicaltrials.gov), and the recent FDA approval of a gene therapy for spinal muscular atrophy. By producing recombinant AAV with variant capsids, the trophism of the viral vectors can be manipulated to target different types of cells and regions. The most welldocumented results are for intrathecal administration using AAV9, but there are several additional novel capsids that have been reported that might be appropriate for delivery of intrabodies in neurodegenerative diseases (Challis et al., 2019; Huang et al., 2019; Hudry and Vandenberghe, 2019) .
Intrabody protection of transplanted stem cells
Data from human studies of transplanted stem cells for Parkinson's disease (PD) showed that a measurable percentage of the donor cells acquired Lewy body aggregates of misfolded α-syn. Misfolded isoforms of the protein are known to be secreted from affected cells, where they can be taken up by unaffected neighboring neurons (Chu and Kordower, 2010; Dehay et al., 2016; Kordower and Brundin, 2009 ). These complexes can then recruit the otherwise properly folded α-syn into Lewy structures. If the overall cellular levels of α-syn could be reduced in the donor cells, transmission from affected host cells is delayed. Intrabodies offer an ideal method for stably "immunizing" donor cells from the exogenous threat. Studies also support a similar, although less robust, process in Huntington's disease (HD) (Masnata and Cicchetti, 2017) . There is also evidence that there is accumulating misfolded tau in embryonic neurons that were transplanted into HD brains many years ago (Maxan and Cicchetti, 2018) . Again, there might be protective option with intrabodies that could be expressed from genes that are transfected into the donor cells ex vivo, in order to reduce the transmission of misfolded species into these cells.
Targets for Huntington's disease
HD is an autosomal dominant neuropsychiatric disorder, triggered by the misfolding of the very large (3188AAs) huntingtin protein (Bates et al., 2015; Stoyas and La Spada, 2018) . Many studies have identified protein fragments of the N terminus as the pathogenic species, although there is some controversy as to the exact size of the fragment (There may, in theory, be more than one) (Neueder et al., 2017) . HD was the second disease gene shown to harbor a trinucleotide CAG repeat that is capable of expanding both integenerationally, leading to anticipation/ earlier onset in succeeding generations; and somatically, potentially leading to more severe cellular phenotypes with aging. HD can be considered a paradigm disease, given that it has been at the leading edge of technologies for gene mapping and identification, as well as development of novel therapeutics. The latter is facilitated by a series of well-defined cellular and animal models, plus a patient population in which penetrance is complete.
Given that the abnormally folded polyQ protein fragments accumulate intracellularly, the intrabody approach is especially appealing. Since gene carriers can be identified while the disease is still in the premanifest stage, it should be possible to target the earliest step in the pathogenic cascadethe initial misfolding of the expanded polyQ tract (Gupta et al., 2012) . Multiple studies have shown that the kinetics of the misfolding is sensitive to the context of the surrounding residues (Robertson et al., 2011; Wetzel, 2012) . Intrabodies therefore offer options to alter this misfolding itself, while also manipulating turnover, subcellular localization (preventing nuclear accumulation) (Miller and Messer, 2006) , and interactions with abnormal partner proteins ( Fig. 1 ).
Specific anti-HTT intrabodies
As noted above, the full-length huntingtin (HTT) protein is 3188 AAs. However, N-terminal fragments of the mutant HTT (mHTT) protein, expressing an expanded polyQ ranging from moderate (Q46) to severe (Q82; Q103; Q175), can lead to HD phenotypes in cellular and animal models. Recombinant scFv and dAb antibodies have therefore been selected based on this fragment. Candidate clones have been isolated from phage or yeast surface-display libraries, as well as from hybridoma cell lines. Initial targets in both the Messer and Patterson labs were the amyloidogenic expanded polyQ. However, we now recognize that such anti-fibrillar intrabodies can stabilize the otherwise kinetically active fibrils, and serve to increase both the size and the toxicity of misfolded expanded polyQ HD (Khoshnan et al., 2002; Kvam et al., 2009) . Therefore, an approach based on altering the context of the polyQ has been utilized, targeting both N and C-terminal peptides flanking the polyQ. The N-terminal 17 AA (N17) and 20 AA sequences were tested, since post-translational modifications can affect the intracellular localization and toxicity. The proline-rich C-terminal to the polyQ was also known to affect overall toxicity of mHTT, and monoclonal antibodies to this region were available for engineering ( Fig. 3) .
N-terminal to polyQ
The first anti-HTT intrabody, scFvC4 was selected from sub-pools of a naïve human spleen scFv phage-display library (Sheets et al., 1998) by iteratively panning in solution against the unmodified N-terminal 1-17 HTT peptide (Lecerf et al., 2001) . Although many scFv fragments are known to fold poorly in the reducing environment of the cytoplasm, this construct displayed excellent intracellular folding properties. This is particularly important when the cytoplasm is already under proteostatic stress due to the underlying disease process, and analysis of an unrelated control scFv from the same library showed exacerbation of the misfolding of the mHTT Exon1-GFP fragment. Later experiments determined that scFvs with negative charges at neutral pH (including scFvC4) are better cytoplasmic candidates (Kvam et al., 2010) . In vitro affinity of scFvC4 is high (ca. 8 nM). The Messer group has shown that gene expression of this candidate can counteract in situ length- dependent mHTT Exon1 aggregation and toxicity in human and animal cell lines, and organotypic slice cultures (Kvam et al., 2009; Lecerf et al., 2001; Miller et al., 2005a; Murphy and Messer, 2004; Scott et al., 2007) . Furthermore, this intrabody elicits turnover of soluble mHTT Exon1 fragments much more efficiently than it does for endogenous full length HTT (Miller et al., 2005b) . Sparing of the full-length protein will be safer in vivo than turning over the wild-type full-length protein, which has multiple normal functions (Cattaneo et al., 2005) . Drosophila carrying HTT-exon-1-Q93 transgenes with a UAS promoter progress through the larval stages but show reduced temperature-dependent eclosion rates. The adult lifespan was shortened to~6-9 days, and there is accumulating mHTT Exon1 leading to neurodegeneration of the photoreceptor cells of the eye. (Steffan et al., 2004) . Candidate intrabodies can be introduced into the mHTT lines as transgenes using a breeding protocol that yields pan-neuronal co-expression of the HTT and intrabody genes. The scFvC4 gene was expressed in flies using the UAS-GAL4 system, so that crossing the elav-GAL4 flies to those harboring both the UAS-scFvC4 and UAS-HTT Exon1 gave pan-neuronal co-expression. In three separate sets of breeding experiments, ScFvC4 expression corrected eclosion from 23% to 100%, and slowed mHTT aggregation in the photoreceptors, while rescuing the neurodegeneration (Wolfgang et al., 2005) . Although lifespan was extended by 30%, flies still died prematurely. Histology revealed both aggregates and neurodegenerations emerging in the older adults. Therefore, we tested several combinatorial approaches to improve phenotype. McLear et al. (2008) tested co-expression of the chaperone protein HSP70 with scFvC4 which showed a modest, yet significant, additive effect on survival of adult HD flies. However, intrabody alone was more effective at slowing neurodegeneration and aggregate formation, with no additive effect. Furthermore, a direct combinatorial approach expressing a scFvC4 -HSP70 fusion intrabody decreased lifespan compared to HD flies alone, possibly due to misfolding of the fusion protein. Cystamine testing of adults showed additive neuroprotection, without an increase in lifespan. Larval treatment of with intrabody plus drug did improve lifespan compared to either alone, without increased neuroprotection, as determined histologically (Bortvedt et al., 2010) . Pilot studies with nicotinamide seemed even more promising, and this work was moved directly into mice for small molecule testing, initially in the absence of intrabody. Using nicotinamide, there was rescue of motor deficits and upregulated PGC-1alpha and BDNF gene expression in HDR6/1 mice (Hathorn et al., 2011) , oddly without concomitant neuroprotection. These themes of eventual breakthrough of an initially effective intrabody therapy, reflected to some extent in the separation of neuroprotection vs. lifespan, has provided important guidance for mammalian studies. Further combinatorial studies are clearly justified.
Transgenic mice, see (Crook and Housman, 2011) for review, have been invaluable for elucidating aspects of the pathogenesis and disease progression in HD. While full-length models including human mHTT expressed from yeast or bacterial artificial chromosomes (e.g., YAC128 and BAC97 (Gray et al., 2008; Miller et al., 2003; Slow et al., 2003) or knock-in, e.g., (Menalled et al., 2003) , in theory provide the most faithful model of the full disease, their extended timecourse and sometimes modest symptoms during the relatively short lifespan of the mouse, make them challenging for the screening of candidate intrabodies. Initial preclinical intrabody studies have therefore focused mainly on the R6 transgenic lines (Mangiarini et al., 1996) , which are available on an inbred C57Bl6 genetic background. Motor symptoms are generally apparent in 6-12 weeks (R6/2 and R6/1 respectively), with a lifespan 12-14 weeks for R6/2 and 30-40 weeks for R6/1 as described below. To date, the R6/1 mouse appears to offer the most useful combination of timecourse for both disease manifestation and window of opportunity for correction. Studies in a range of mouse models have recently been reviewed (Farshim and Bates, 2018) , while larger animal models such as sheep will hopefully be available to test intrabody approaches soon (Morton, 2018) .
scFvC4 was delivered using intrastriatal AAV2/1 into B6.HDR6/1 mice. Both the size and number of HTT aggregates were significantly reduced initially and through the middle stages of disease, with confirmation that the effect was limited to transduced cells (Hathorn et al., 2011; Snyder-Keller et al., 2010) . However, as was observed in the fly model, the fraction of large aggregates increased over time (weeks to month, rather than days, in this case.) The data fit with the hypothesis that the mHTT Exon1 protein can rapidly misfold during the time that the antigen-antibody complex is dissociated. PolyQ kinetic changes are known to be very active, and if the polyQ becomes fibrillar, it is insoluble and can no longer be corrected by the intrabody. Development of bifunctional fusions with degron sequences that facilitate turnover of bound species prior to dissociation offer a powerful new approach to enhancing the intrabody function and are discussed below. A second anti-N-term intrabody, VL12.3, was initially selected from a non-immune human yeast surface display library, using HTT AA1-20 rather than AA1-17 as a target. The binding activity resided exclusively in the variable light chain; therefore the intrabody was studied and engineered as a single-domain intrabody (VL) (Colby et al., 2004a) Cytoplasmic efficacy was engineered via iterative substitutions of cysteine (which interacts with the reducing environment) with hydrophobic residues, and multiple rounds of affinity maturation (Colby et al., 2004a; Colby et al., 2004b) . Southwell et al. tested AAV-mediated VL12.3 delivery in both R6/2 HTT Exon1 transgenic mice, and a model made by injecting mHTT Exon1 using a lentivirus. Lentivirus drove very high expression of mHTT Exon1 and co-administration of VL12.3 improved behavior and neuropathology (Southwell et al., 2009 ). However, VL12.3 actually modestly accelerated disease in the R6/2 model, possibly due to higher levels of antigen-antibody complex in the nucleus of transduced cells (Southwell et al., 2008) ,
Comparisons of the in vivo efficacy of the two anti-N-term antibody fragments with the crystal structures offers an opportunity to fine-tune our concept of epitope dominance, antigen choice, and target validation. scFvC4 was selected in solution AAs 1-17, while VL12.3 was selected by yeast surface binding to AAs 1-20, and extensively engineered. The crystal structure of scFvC4 in complex with its antigen shows that the first 15 HTT residues are in intimate contact with the intrabody (De Genst et al., 2015) . Contact residues of the VL12.3 cocrystal are AAs 5-18 (Schiefner et al., 2011) (Fig. 2b ). These differences encompass the HTT Exon1 Thr-3 and Ser-16 post-translational sites, which have been implicated in subcellular localization and toxicity (Aiken et al., 2009; Gu et al., 2009; Steffan et al., 2004; Viteri et al., 2010) , which is especially interesting in light of our finding that the two intrabodies show differential nuclear/ cytoplasmic localization in situ and in vivo (Butler et al., 2014) .
C-terminal to polyQ
The Patterson group has investigated a series of both monoclonal antibodies and intrabodies that target the region C-terminal to the polyQ. This includes a polyprolline (polyP)-rich region that has been shown to modulate polyQ aggregation (Qin et al., 2004; Rockabrand et al., 2007 ). An initial scFv was cloned from the variable domains of the monoclonal antibody MW7, which binds to the two polyP stretches. This construct reduced mHTT aggregation and enhanced survival in an HEK293 culture model of HD (Khoshnan et al., 2002) . The target may be shared by other cellular proteins, and the scFv probably had the suboptimal solubility which is common to many scFvs developed from monoclonal antibodies. Additional anti-proline-rich domain intrabodies (Happ 1 and Happ 3) were selected from a non-immune human recombinant scFv phage library (Southwell et al., 2008) . These intrabodies bound as single-domain VLs, and could counteract aggregation and toxicity at lower doses than the scFvMW7 (Southwell et al., 2008) . All three intrabodies accelerated the clearance of the very rapidly-aggregating mHTT Exon1 in HEK293 cells, presumably by allowing the bound target to remain soluble and therefore subject to normal turnover mechanisms (Southwell et al., 2008 ). Happ1 appears to induce clearance of mHTT via enhanced calpain cleavage of the first 15 AA of mHTT followed by lysosomal degradation (Southwell et al., 2011) . Intrastriatal AAV delivery of Happ1 was tested successfully in a series of viral and transgenic HD mouse lines, reducing neuropathology and behavioral abnormalities (Southwell et al., 2011; Southwell et al., 2009) . One model also showed increased body weight and a 30% increased lifespan.
An additional intrabody, INT41 targeting this region has been described by (Amaro and Henderson, 2016) . In a series of short-term experiments, improvements were reported in the phenotype of a PC12 Q73 cell model, as well as aggregation and cognition in AAV6-INT41 R6/2 female mice. Longer-term studies will be interesting, to determine whether the effect wanes with time, due to intrabody dissociation effects, as in the scFvC4 studies above. A more C-terminal scFv intrabody has been cloned from the mouse monoclonal antibody EM48, that was developed as a valuable immunocytochemical reagent for following aggregated protein in mice expressing human HTT (Wang et al., 2008) . In HEK293 cells, this intrabody suppressed the cytoplasmic, but not the nuclear, toxicity of mHTT Exon1 in HEK293 cells. Adenovirus-mediated delivery (primarily into glial cells) into the striatum of N171-82Q HD showed reduced neuropil aggregates, and improved motor deficits of N171-82Q during an 8-week test (Wang et al., 2008) . As above, longer testing is required. Use of AAV vectors would allow examination of effects on neurons and be closer to clinical utility.
Development of bifunctional intrabodies
As noted above, the treatment effect of scFvC4 in both fly and mouse models decreased over time, with clear evidence of escape of intrabody-mediated mHTT Exon1 clearance into increasingly large insoluble complexes, most probably during the brief periods of dissociation of the intrabody. We therefore sought to target the bound intrabody-antigen complex for rapid degradation using the cells' own clearance mechanisms.
The ubiquitin-proteasome-system (UPS) is believed to play an important role in the clearance of the soluble isoform of mHTT (Li et al., 2010; Li and Li, 2011) , while aggregated N-terminal mHTT fragments have been reported to be resistant to degradation by the UPS (Verhoef et al., 2002) , and are subject to degradation by autophagy. In order to clear mHTT while properly folded and bound to intrabody, the Cterminal degron from mouse ornithine decarboxylase (mODC; AA 422-461) was fused onto the C-terminus of scFvC4 to redirect the antigen-intrabody complex into the proteasome. According to the PEST hypothesis, the presence of one or more regions rich in proline (P), glutamic acid (E), serine (S), and threonine (T) in the primary structure of a protein confers susceptibility to rapid intracellular proteolysis (Rechsteiner and Rogers, 1996; Rogers et al., 1986) . ODC, the rate limiting enzyme involved in the biosynthesis of polyamines (Takeuchi et al., 2008) , contains a C-terminal PEST degron and is rapidly degraded in mammalian cells upon binding to antizyme 1 (Ghoda et al., 1989 ) through ubiquitin-independent proteolysis (Zhang et al., 2003) . The carboxyl terminus of mODC has been shown to function as a portable signal for protein degradation. Grafting it on to several stable proteins including trypanosome ODC (Ghoda et al., 1990) , dihydrofolate reductase (Loetscher et al., 1991; Zhang et al., 2003) , green fluorescent protein (Li et al., 1998) and luciferase (Leclerc et al., 2000) was sufficient to induce their degradation. The mODC degron has been proposed to perform two functions: 1) It binds to the lid (19S) of the 26S proteasome (Erales and Coffino, 2014; Murakami et al., 1999) ; and 2) It provides a disordered region that allows for proteasomal entry (Erales and Coffino, 2014) . The scFvC4-PEST (C4-PEST) fusion protein induced significant reduction (~90%) of steady-state mHTT fragment protein levels compared to C4-PEST scrambled control and scFvC4 (Butler and Messer, 2011) . Delivery of the C4-PEST construct using AAV2/1 has shown great success in reducing aggregates over a longer timeframe. However, it is difficult to follow the spread and long-term levels of the PEST constructs histologically, since the level of the unbound intrabodies is also reduced. We also observed some additional localized inflammation that was not present when the parent intrabody was delivered using the same gene therapy vectors, although the viral preparations were done at different times at Univ. Iowa, which could also have been a source of variability. This effect seemed to be independent of the presence of the mHTT transgene and persisted well beyond the time that the AAV itself should have been uncoating and degrading inside the cells. The phenomenon is not universal to the intrabody-PEST candidates, since the two others that we have tested, against α-syn (Chatterjee et al., 2018) , had lower levels of microglial infiltration in one case, and virtually no evidence of an inflammatory reaction in the other. A wider testing of intrabody-PEST fusion constructs will be needed to establish the parameters of a transfer that retains the extremely valuable turnover properties, while avoiding increased inflammation.
Antigen conformation is an important determinant when utilizing intrabody-PEST mediated targeted degradation. It is important to note that scFvC4 specifically targets the soluble portion of the mHTT Nterminal fragments (Miller et al., 2005b) and maintains mHTT in a monomeric soluble conformation. Aggregated/fibrillar mHTT-PEST complexes were resistant to proteolytic degradation, as fusion of the mODC PEST degron to an anti-fibrillar scFv6E, which binds only to fibrillar mHTT fragments, failed enhance the degradation of mHTT Exon1 (Butler and Messer, 2011) . These results are consistent with the hypothesis that aggregated mHTT fragments are resistant to degradation by the UPS (Verhoef et al., 2002) . The Escherichia coli (E. coli) β-Galactosidase (β-gal) is commonly used as a target for proof of principle experiments. β-Gal is a large 120 kDa protein, encoded by the lacZ gene of the lac operon in E. coli, that forms a tetramer (Jacobson et al., 1994) . Sibler et al. transferred the mODC PEST degron onto the anti-β-gal scFv13R4 intrabody (Sibler et al., 2005) , a soluble intrabody that was able to retarget β-gal into the nucleus of mammalian cells when the construct included the SV40 T-antigen nuclear localization signal (NLS) signal peptide. The anti-β-gal scFv13R4-PEST intrabody was rapidly degraded/ destabilized in the absence of antigen; however, the exceptionally large intrabody-tetrameric antigen complex was resistant to proteasomal degradation (Sibler et al., 2005) .
When engineering for intrabody-PEST-mediated targeted degradation, properties of the intrabody must also be taken into consideration. There may be many classes of intrabodies that are not completely destabilized by the addition of the mODC PEST degron. In contrast to the anti-β-gal scFv13R4-PEST intrabody, which is readily destabilized, scFvC4-PEST and scFv6E-PEST intrabodies did not undergo appreciable turnovertheir steady-state levels were only reduced by~25%, and they were independent of antigen availability (Butler and Messer, 2011) . scFvC4, scFv6E, and scFv13R4 belong to different framework families. The framework for scFv13R4 underwent several rounds of mutation and selection to improve intracellular solubility, and differs significantly from consensus antibody framework sequences (Martineau et al., 1998) . The anti-β-gal scFv13R4 parent intrabody also differs from anti-HTT scFvC4 in solubility calculations (Kvam et al., 2010) . It is possible that the different degradation rates of the intrabody-PEST fusions are due to substrate unfolding within the proteasome. This hypothesis is supported by experiments which manipulated the folding stability of two different C-terminal mODC fusion proteins (Titin and DHFR). An increase in substrate stability resulted in decreased turnover rate (Henderson et al., 2011) . Empirical testing of intrabody-PEST fusion constructs is quite straightforward in tissue culture and can quickly be performed to identify the most effective fusion constructs for the selective proteolytic degradation of intracellular proteins.
Summary of HD intrabody studies: HD is serving as a paradigm disease for the intrabody approach. The availability of a range of models, plus data ranging from cellular to structural, is allowing us to interrogate the function and importance of specific domains and AAs on targets, from molecules to brains. Cytoplasmic solubility is an ongoing battle, particularly in an environment where the protein folding machinery is already under considerable stress. Another critical issue is engineering the intrabodies to circumvent the long-term kinetic effects of dissociation of the intrabodies from their targets, followed by eventual formation of irreversible fibrillar structures. Efficient delivery via gene therapy is a cutting-edge field of investigation that is being pioneered by the rare disease gene replacement community, and ripe for testing here, as noted above.
Parkinson's disease and related synucleinopathies
Misfolded α-syn has been shown to accumulate within intracellular inclusions throughout the brain and, in some cases, peripherally in a range of neurodegenerative diseases including PD, dementia with Lewy bodies, multiple systems atrophy, and related disorders. These inclusions; Lewy bodies and Lewy neurites, are correlated with the dysfunction and eventual degeneration of the cells in which they accumulate (Baba et al., 1998; Ingelsson, 2016; Spillantini et al., 1998) . Although the detailed mechanisms of the triggering and neurotoxic mechanisms are complex and still a major topic of investigation, overexpression of α-syn, when combined with altered chaperone activity and/or aberrant protein degradation machinery, can clearly yield excessive proteostatic stress (Kanda et al., 2000; Pukass et al., 2015; Schildknecht et al., 2013; Shtilerman et al., 2002; Xiang et al., 2013) . The products of these stressors accumulate intracellularly, and the misfolded forms can also be extruded leading to prion-like cell-to-cell transmission of toxic α-syn species, and spreading of pathology (Dehay et al., 2016; Kordower and Brundin, 2009; Kordower and Brundin, 2016; Wang et al., 2018) . Extracellular immunotherapeutics have therefore been a major focus of study. (El-Agnaf et al., 2017; Spencer et al., 2017; Tran et al., 2014; Valera et al., 2017) However, reduction of the intracellular proteostatic load via targeting of monomers offers a more basic approach to the pathogenic mechanism.
The small size, hydrophobic interaction region, and partially unfolded structure, make α-syn a radically different target than HTT. Consideration of the development of intrabodies against this target therefore greatly expands our knowledge of parameters and optimization approaches for intrabodies in general, while providing a novel set of candidate clones as direct therapeutics. (Messer and Joshi, 2013) . The non-amyloid component (NAC) hydrophobic domain of α-syn is prone to aggregation and has been shown to be critical for misfolding and abnormal interactions in multiple models based on NAC region deletions. (Giasson et al., 2001; Lynch et al., 2008; Periquet et al., 2007) . However, attempts to raise antibodies specific to this region are largely unsuccessful, presumably due to the lack of availability of the domain when the protein is folded in vivo. Screening of libraries of antibody fragments can bypass this difficulty using direct screening of peptides. An initial screen of a yeast surface display library of human scFvs using a peptide (AA53-87) from the α-syn NAC yielded a series of positive clones. These were then verified with the smaller peptide (AA62-78) for relative affinities. The strongest binder was clones #3 and 14, with several others positive. Surprisingly, the most protective clone when tested in situ for viability rescue when cells are challenged to overexpressed α-syn mutant A53T was scFvNAC32. The clone #14 was found to be an unprotected VH, which do occur with some frequency in libraries due to the library production protocols. The singledomain VH clone was not soluble in cytoplasm. scFvNAC3 did express as a highly soluble construct intracellularly, but apparently the epitope it binds to was either buried or not protective. This study therefore provided several critical lessons for intrabody development (Lynch et al., 2008) . The strongest binders from an in vitro assay may be dysfunctional as intrabodies due to insolubility in the reducing environment of the cytoplasm in general, or when combined with existing proteostatic stress in disease cells. Even soluble candidates may bind to epitopes that are unavailable under particular conditions of folding or modifications of the target. These factors need to be determined empirically in secondary functional screens using appropriate cell types. In some cases, further engineering can be valuable, and can serve multiple purposes. In the best example to date, the addition of bifunctional fusions with a proteasome targeting signal that also increases solubility via increasing negative charge, has allowed for the "rescue" of our highest binding anti-syn clone (Butler et al., 2016; Joshi et al., 2012) .
Using an immunization and library production approach, a separate pool of VHH nanobodies was selected from an immune dromedary phage-display library that used full-length α-syn protein as an immunogen (Guilliams et al., 2013) . The screen yielded Nbsyn87 and Nbsyn2, which have been investigated structurally, and found to target the C-terminal region of α-syn. This is a potentially protective target domain on the protein, since it is known to contain post-translational modifications affecting pathogenic triggers of misfolding reviewed in (Eliezer, 2013) . Nbsyn87 was shown to interfere with mutant α-syn aggregation events in vitro (El-Turk et al., 2016) , and was therefore compared in situ to VH14 after both were fused to the PEST degron. These studies confirmed that confirmed that the fusion of the mODC PEST degron to both VH14 and Nbsyn87 reduced α-syn aggregation, increased clearance of α-syn, and offered protection against toxicity induced by overexpression of α-syn in ST14A cells. (Butler et al., 2016) . It appeared that, while the camelid clone provided a somewhat stronger reduction in α-syn levels, the human VH14-PEST clone offered statistically stronger survival benefits to the cells. Nbsyn2, which binds to a longer and most C-terminal α-syn peptide, did not function to decrease excess α-syn levels, and was not effective. Both successful candidates in situ were then moved to in vivo studies, using a rat viral gene therapy model of α-syn overexpression (Chatterjee et al., 2018) . Both nanobodies were able to offer some protection when young adult rat substantia nigra was first injected with AA5-α-syn, followed 3 weeks later by AAV5 nanobody-PEST, to mimic treatment of brains that are already involved in the disease process. Multiple parameters were assayed at 8-16 weeks post-injection, with postmortem histopathology. The most substantial correction (VH14-PEST > Nbsyn87-PEST) was a reduction in phosphorylated Serine-129 (p-S129) α-syn, which correlates strongly with pathological aggregation. Striatal tyrosine hydroxylase rescue was significant and similar for both constructs, with modest preservation of the tested gross motor behaviors, again VH14-PEST > Nb87-PEST. It may be significant that Iba-1-positive microglial staining was higher in Nbsyn87-PEST rats than with VH14-PEST. This increase in localized inflammation, while less than was observed with the anti-HTT scFvC4, may have contributed to the somewhat lower protection offered by the C-terminal intrabody in vivo. It will be extremely important to further investigate the parameters of this inflammatory response, since there are multiple differences between the two intrabodies; and to engineer therapeutic candidates where it is minimized. The fact that one of our most successful constructs had a very low inflammatory response suggests that this is quite feasible, given sufficient in vivo data. Additional candidate scFvs and nanobodies have been selected and tested in vitro targeting various species of α-syn, including oligomeric, protofibrillar, and fibrillar forms, although their use as intrabodies has not been tested extensively rev (Bhatt et al., 2013; De Genst et al., 2014) .
Tauopathies
Tauopathies are heterogeneous progressive neurodegenerative disorders of the central nervous system that share a common feature of abnormal tau hyperphosphorylation and aberrant tau aggregation. To date, there > 20 clinicopathological tauopathy disease classifications, including Alzheimer's disease (AD), the most common tauopathy. In many of the tauopathies, co-pathologies have been shown to influence the clinical phenotype, making it difficult to identify the mechanisms of tau-dependent neurodegeneration (Rojas and Boxer, 2016) . For example, the neuropathological hallmarks of the AD brain consist of two types of fibrous insoluble material: extracellular amyloid plaques and A. Messer and D.C. Butler Neurobiology of Disease 134 (2020) 104619 intracellular neurofibrillary tangles and threads (NFT) composed of hyperphosphorylated tau protein (Crespo-Biel et al., 2012) . Identification of missense mutations within the MAPT gene that cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17 T) led to the understanding that misfolded tau causes neurodegeneration (Wolfe, 2012) . Over 53 mutations within the MAPT gene have been identified from over 150 families to cause FTDP-17 T (Im et al., 2015) . Under physiological conditions, tau is a soluble protein, however, in pathological states it becomes hyperphosphorylated and accumulates into toxic oligomers and insoluble neurofibrillary tangles (NFTs) that propagate to other brain regions, leading to synaptic loss and neuronal death. These pathological changes in tau strongly correlate with neuronal loss and cognitive dysfunction (Goedert and Spillantini, 2017; Sigurdsson, 2014) . Promisingly, tau aggregation and toxicity have been shown to be reversible if tau levels are reduced in animal models (Khlistunova et al., 2006; Wang et al., 2010) , thus suggesting therapeutic strategies aimed at reducing tau protein could prevent disease progression.
To circumvent the potential effect of a proteasomal targeting signal on excessively reducing steady-state levels of the unbound intrabody prior to antigen binding, Melchionna and Cattaneo created inducible suicide intrabodies by fusion with IκBα, which must be activated by TNFα (Melchionna and Cattaneo, 2007) . Melchionna and Cattaneo demonstrated that tau could be targeted to the proteasome for degradation with an anti-tau scFv#2 intrabody fused to IκBα in N2A immortalized cells. Their anti-tau intrabody reduced aggregation and apoptosis triggered by tau overexpression (Melchionna and Cattaneo, 2007) . Unfortunately, this strategy is suboptimal as a therapeutic due to potentially severe side effects caused by the requirement for the inflammatory cytokine TNFα, to initiate protein degradation. In fact, reduction of TNFα is considered to be a valuable therapeutic strategy for AD (Decourt et al., 2017) . The Cattaneo lab recently applied this regulated approach to validate a conformational-sensitive tau sensor that can be used to investigate the changes in the 3D conformation and aggregation state under physiological and pathological conditions in living cells (Di Primio et al., 2016) , which may be a reasonable application of the technology. Because misfolded tau can propagate in prionlike fashion (Goedert, 2015) , and because of its causal role in disease, it is a prime target for therapeutic strategies. Reducing tau is likely to be well-tolerated given that mice can develop and survive without tau (Lopes et al., 2016) . In addition to tau knockout mice, several studies have illustrated that reduction of tau is tolerable (DeVos et al., 2018; DeVos et al., 2013; DeVos et al., 2017; Silva et al., 2019) . We have recently identified a series of anti-tau scFv clones that, with further engineering as C-terminal mODC PEST fusions, successfully relocalized GFP-labeled tau to the proteasome for clearance in ST14A cells. It is notable that the responses were variable and did not correlate to the antibody framework or any other parameters that we have identified to date. Therefore, efficacy of intrabody-PEST constructs must be established empirically.
The 2 N isoform of tau has recently emerged as a potential therapeutic target. Within the central nervous system (CNS), alternative splicing of the MAPT gene at exons 2, 3, and 10 produce six isoforms of tau that are classified based on their microtubule binding domain repeat number (3R or 4R). The isoforms are further classified by the presence of N-terminal projection domains termed (0 N, 1 N, and 2 N) (Kolarova et al., 2012) . The expression of tau within the brain is developmentally regulated with 0N3R tau being the predominant isoform during fetal development. In adults, there is an equal distribution of 3R:4R tau with 1 N > 0 N > 2 N (Kolarova et al., 2012) . 2 N tau has been shown to preferentially interact with proteins implicated in neurodegenerative disease (Liu et al., 2016) . Passive immunization with the anti-tau scFvRN2N, which is specific for the 2 N isoform of tau, was able to reduce anxiety-like behavior and tau hyperphosphorylation in of P301L human tau transgenic pR5 mice (Nisbet et al., 2017) . The scFvRN2 N inhibited GSK3β phosphorylation of tau at N-terminal sites (Ser202 and Thr231) in vitro (Nisbet et al., 2017) . The scFv is hypothesized to enter neurons through bulk endocytosis and evades lysosomal degradation through an unknown mechanism (Nisbet et al., 2017) . Transiently opening the blood-brain barrier by repeated focused ultrasound in a scanning mode enhanced the delivery and efficacy of scFvRN2 N by increasing the amount of antibody delivered to the brain, as well as into neurons (Nisbet et al., 2017) .
Amyloid beta (Aβ) and Alzheimer's
With the failure of antibody therapies against Aβ in human clinical trials, it is possible that for the large majority of the cases, the pathogenic cascade is too far advanced from the initial Aβ trigger to make modulation of that molecule a useful target. However, there are genetic cases that could theoretically be treated at earlier stages, and much earlier diagnoses might be possible in the future. Intrabodies delivered using gene therapy can be delivered directly to the brain, or potentially use a viral vector that can enter the brain from the periphery and target specific cells. A phage display synthetic library derived from such fragments yielded a VHH specific to Aβ fibrils (Habicht et al., 2007) . Further examples are offered in (Ryan et al., 2010; Sudol et al., 2009 ). The potential of Aβ intrabodies has been reviewed by Marschall and Dubel (Marschall and Dubel, 2016) and the current status of AD immunotherapy is the subject of a review in this volume. One very recent contribution to the use of highly engineered candidates is the work from the Sierks lab, which reports a bispecific scFv construct that both blocks the β-secretase cleavage site and increases α-secretase cleavage, with positive effects in a mouse model (He et al., 2019) . This construct was delivered to the liver via AAV gene therapy, and the protein was engineered to cross the blood brain barrier. It is therefore effective against an intracellular process when transported into the cell from outside. It will also be interesting to see whether the issue of irreversible changes during the dissociative phase of the binding can be counteracted by this bispecific approach in the long term.
Amyotrophic lateral sclerosis (ALS)
While the majority of ALS cases appear to be sporadic, up to 20% of cases have been found to have genetic backgrounds. Of these, the most commonly identified are C9orf72, TARDBP (TDP43), superoxide dismutase (SOD1) and FUS (Hardiman et al., 2017) . Proteins encoded by the first three genes are all candidates for intrabody therapies, and preclinical work is in progress. Mutant forms of SOD1 have been reported to undergo specific forms of misfolding, which may also occur spontaneously, expanding the potential of therapeutics that recognize the specific misfolded conformer (Ghadge et al., 2013) ; More recently, the group (Ghadge et al., 2019) reported AAV9 gene therapy encoding anti-SOD1 scFvs, selected from a phage display library, delivered IV to either neonatal or 120 day old G93ASOD1 mice. The former showed expression in motor neurons, while the latter was mainly astrocytic. However, both showed delayed duration and longer survival than control (GFP)-injected mice. Patel et al. (Patel et al., 2014) examined the effect of D3H5 scFv (derived from a monoclonal antibody with a known specificity for misfolded SOD1) on ALS pathogenesis in the G93A model. After a single intrathecal injection of D3H5-AAV 2/1 scFv at 45 days of age, multiple parameters of disease onset were delayed, and lifespan was extended. Notably, the scFv was secreted as well as localized within spinal cord motor neurons, and there was a dose response to levels of scFv. For ALS, mixing experiments (mutant neurons +WT glia and vice versa) have shown that there are both neuronal and glial components to the disease, and rescue via transduction of glia may have significant beneficial effects.
TDP-43 proteinopathy
TDP-43 has been found to misfold and mislocalize in ALS as well as A. Messer and D.C. Butler Neurobiology of Disease 134 (2020) 104619 a number of other neurodegenerative disorders. It is therefore an excellent candidate for intrabody therapies applicable to multiple diseases. Pozzi et al. (Pozzi et al., 2019) have reported an scFv produced from a pool of monoclonal candidates selected against RRMI domain of TDP-43. In multiple cell tests and using intracranial as well as intrathecal AAV delivery of the gene for this construct, they show protection against TDP-43 proteinopathy. Mouse studies were conducted using 8-month-old TDP-43 A315T mice injected intrathecally with scAAV2/9. Controls included viral constructs expressing an scFv against GFP. They also report moderate, non-pathogenic increased turnover of the target protein even in the absence of a peptide fusion to enhance degradation. There were effects from the intracellular scFv, as well as evidence that the secreted scFv can be recycled into cells from the outside, and possibly also act at a distance to counteract inflammatory processes.
Prions
Transmissible spongiform encephalopathy (TSE), or prion disease, is spread exclusively as a protein, and the intrabody approach is therefore a particularly valuable one. Misfolding of the normal cellular form of the prion protein (PrP C ) has been shown to allow both transmission and pathogenesis of TSE diseases (Aguzzi and Haass, 2003; Prusiner, 2001) . Biocca, Cardinale and colleagues developed an anti-prion scFv, which they fused to the endoplasmic retention signal KDEL. This prevented the conversion of normal to scrapie isforms (PrP C -PrP Sc ), as well as accumulation of the misfolded form, which reduced its infectivity (Cardinale et al., 2005; Vetrugno et al., 2005) . Of particular note, they created a secretory form of the scFv, which, although it can be found in the medium of cultured neuronal cells, appears to function by re-directing the intracellular form of the prion to the proteasome. Both scFvs and nanobodies have contributed to important background structural studies. An scFv against the unstructured domain of the bovine form of PrP was extensively engineered to pM affinity and has been valuable for crystallographic studies (Luginbühl et al., 2006) . Anti-prion nanobody studies by Abskharon RN et al., (2010 and are also notable for their antibody engineering work on this approach (Abskharon et al., 2014; Abskharon et al., 2010) . Given the new options for gene therapy delivery of nanobodies and scFvs, there should be opportunities for novel therapeutics arising from these older studies.
Toxins
Several toxins are known to act intracellularly in neurons. An example of using an intrabody to protect against Botulinum neurotoxin, which cleaves SNARE proteins and inactivates neurotransmitter exocytosis in neuronal cells, is provided by the Shoemaker group, which develops customized alpaca libraries of VHHs. In this example, the nanobody was able to inhibit the protease activity, protecting cells that were transfected with the VHH gene (Tremblay et al., 2010) .
Development of control intrabodies for in vivo studies
Protein folding is a critical issue for scFvs and single domain nanobody intrabodies that are to be expressed and retained within cells as intrabodies. This is especially important given that in neurodegenerative diseases with misfolded proteins, cells are already under proteostatic stress. If the intrabody misfolds, it could exacerbate the disease. Careful consideration should also be taken when selecting control intrabodies. A poorly soluble intrabody directed against an irrelevant antigen may in fact exacerbate the proteostatic burden and artificially elevate the levels of cellular toxicity. For instance, the anti-β-Gal scFv1F4 intrabody forms insoluble aggregates in mammalian cells and is toxic (Sibler et al., 2003) . To control for the effects of both protein overexpression and proteasome degradation of PEST-tagged intrabodies, we generated a control single domain intrabody against an antigen that is not expressed in any of our test systems. VHHB8 is a well-characterized camelid nanobody that binds to Botulinum Neurotoxin, and has demonstrated excellent intracellular solubility in our test system (Kvam et al., 2010) .
Selective activation of chaperone mediated autophagy
An alternative approach for reducing the levels of mHTT has involved bifunctional anti-huntingtin intrabodies that direct their bound antigens into autophagic/lysosomal pathway of intracellular protein degradation. In the chaperone mediated autophagy pathway (CMA), proteins that contain HSC70 binding motifs (KFERQ and VKKDQ) are recognized by HSC70, which channels them to the surface of lysosomes for degradation (Bauer et al.; Cuervo and Wong, 2014) . Lamp2a binds the targeted protein, and translocates it across the lysosomal membrane where it is degraded (Cuervo and Wong, 2014) . Bauer et al. fused a pair of HSC70 binding motifs to polyQ binding protein (QBP1) to direct mHTT to the chaperone mediated autophagy (CMA) lysosomal pathway of protein degradation. QBP1 was designed after monoclonal antibody 1C2, which binds to expanded polyglutamine repeats, and isolated from an 11 AA peptide phage display library (Popiel et al., 2011) . AAV2 transduction of QBP-HSC70BM into the striatum of HDR6/2 mice resulted in a 40% reduction of soluble mHTT Exon 1, with~80% reduction of mHTT aggregation (Bauer et al., 2010) . We fused the HSC70BM to scFvC4 and observed a similar 30% reduction of soluble mHTT, with nearly 100% reduction of aggregates. These proof of concept studies suggest that additional misfolded proteins, such as tau, could be directed to the CMA pathway for degradation.
Potential of heterologous intrabody therapeutics
It is becoming increasingly apparent that reductions in one misfolding protein could have beneficial effects on other disorders thought to be primarily triggered by different proteins. In HD, pre-clinical studies have shown that α-syn can potentiate the neurotoxicity of mHTT protein in vitro and in vivo (Corrochano et al., 2012; Furlong et al., 2000; Pocas et al., 2015; Tomas-Zapico et al., 2012) . In culture experiments where α-syn and mHTT Exon1-GFP were co-expressed, treatment with an anti-α-syn nanobody was able to reduce aggregation of the mHTT Exon1-GFP (Butler et al., 2016) . Furthermore, synuclein and tau have been shown to co-aggregate with mHTT protein in HD patients (Charles et al., 2000; St-Amour et al., 2018; Vuono et al., 2015) . Recent studies have identified tau (St-Amour et al., 2018; Vuono et al., 2015) and syn (Charles et al., 2000; St-Amour et al., 2018) co-pathology in HD patients' cortical and subcortical neurons, which may contribute to disease severity. Therefore, reductions of α-syn or tau utilizing intrabodies could also serve as adjunct HD therapeutics. Due to their small size, it is quite feasible to deliver two or more intrabodies in a single multifunctional construct. A similar approach holds promise for combinations of tau, α-syn and TDP43. Numerous studies have reported crosstalk between synuclein and tau (Moussaud et al., 2014; Nonaka et al., 2018) , and a recent review covered cross-seeding more broadly (Lim, 2019) . In all of these cases, it should be possible to multiplex intrabodies to target multiple aspects of the misfolding. It may also be the case that even a single intrabody against a heterologous protein could have value as a therapeutic.
Concluding remarks
Engineered antibody fragments that can act intracellularly will be important therapeutics for neurodegenerative diseases that are triggered by intracellular processes. Intrabodies/ nanobodies offer distinct advantages over antisense and editing nucleic acid drugs, since they can target modified forms of proteins, including post-translational modifications and conformational epitopes. Specificity can be very precise, and binding affinities, including on and off rates, are controllable.
Cellular localization can be manipulated via fusion proteins that are readily designed. With a wide range of selection and molecular optimization approaches that are influenced by very successful work on cancers, infectious, and inflammatory diseases, increasingly detailed options for the most effective targets are under continuous development. Delivery to the brain, which has been a constant challenge to neuroimmunotherapeutics, is facilitated with constructs that can be delivered as genes using a range of new and emerging protocols, including some in current clinical trials. As knowledge of the pathogenic processes that underlie neurological diseases increases, additional targets amenable to this approach will become available. Earlier identification of disease, in some cases also using these antibody fragments as in vivo or body fluid probes, will further expand opportunities for these optimized reagents.
